Compare Novavax Inc (NVAX) vs Uranium Energy Corp (UEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Uranium Energy Corp — how do they compare? Novavax Inc trades at $8.12 (market cap $1.30B), while Uranium Energy Corp trades at $9.55 (market cap $4.65B). The key difference: Uranium Energy Corp is far larger — about 3.6× Novavax Inc's market cap, and Novavax Inc is trading nearer its 52-week high, Uranium Energy Corp nearer its low. Which is the better fit depends on your goals.
| NVAX | UEC | |
|---|---|---|
Market Cap | $1.30B | $4.65B |
Sector | Health | Energy |
52-Week High | $11.19 | $20.14 |
52-Week Low | $6.22 | $8.00 |
Enterprise Value | $800.50M | $4.16B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $8.08, down 1.64% on the day, with a bearish technical signal but strong recent earnings beats. The company reported $1.12B revenue in 2025 with a net income of $440.30M, though 2026 projections show a return to losses. Analyst consensus is bullish with a $14.00 price target, but negative shareholder equity and cash flow concerns persist.
Outlook remains mixed: strong valuation ratios and analyst support suggest upside potential, but negative cash flows, high liabilities, and projected 2026 losses pose significant risks. Investor sentiment is cautious amid recent stock declines and shareholder dissent highlighted in recent news.
Uranium Energy Corp (UEC) trades at $9.40, up 1.29% today, amid bearish technical signals and challenging fundamentals. The stock shows negative profitability with a net income margin of -513.24% and has missed earnings estimates in two of the last three quarters. Recent news highlights operational pressures and strategic positioning in the uranium sector, with analyst sentiment remaining largely positive despite financial headwinds.
The outlook for UEC hinges on execution of its in-situ recovery ramp-up and uranium sales timing. Investment opportunity lies in its debt-free balance sheet and $794 million liquidity, but risks include persistent losses, high valuation multiples, and reliance on uranium price recovery. Wall Street maintains a buy-heavy consensus, suggesting long-term potential if operational targets are met.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Uranium Energy Corp
Uranium Energy Corp is a leading American uranium mining and exploration company, currently holding the largest resource base and licensed production capacity in the United States. Utilizing low-cost, environmentally friendly In-Situ Recovery (ISR) mining, UEC is a central player in the domestic nuclear fuel supply chain, transitioning from a resource holder to an active producer and refiner to meet the accelerating demand for carbon-free energy.
Read more on UEC →
